XML 29 R12.htm IDEA: XBRL DOCUMENT v3.25.0.1
Revenue and Contract Acquisition Costs
 12 Months Ended
Dec. 31, 2024
Revenue from Contract with Customer [Abstract]  
Revenue and Contract Acquisition Costs Revenue and Contract Acquisition Costs
The following table summarizes the Company’s disaggregated revenue:
Years Ended December 31,
(in millions)202420232022
U.S.$1,509.3 $1,251.0 $884.8 
International523.4 410.1 363.0 
Total Omnipod products
2,032.7 1,661.1 1,247.8 
Drug Delivery38.9 36.0 57.5 
Total revenue$2,071.6 $1,697.1 $1,305.3 
The percentages of total revenue for customers that represent 10% or more of total revenue was as follows:
Years Ended December 31,

202420232022
Distributor A28%28%19%
Distributor B26%24%16%
Distributor C21%19%17%
Deferred revenue related to unsatisfied performance obligations was included in the following consolidated balance sheet accounts in the amounts shown:
As of December 31,
(in millions)202420232022
Accrued expenses and other current liabilities$12.0 $15.4 $16.1 
Other liabilities2.0 1.9 1.6 
Total deferred revenue$14.0 $17.3 $17.7 
Revenue recognized from amounts included in deferred revenue at the beginning of each respective period was as follows:
As of December 31,
(in millions)202420232022
Deferred revenue recognized$15.4 $16.0 $2.1 
Contract acquisition costs, representing capitalized commission costs related to new customers, net of amortization, were included in the following consolidated balance sheet captions in the amounts shown:
As of December 31,
(in millions)20242023
Prepaid expenses and other current assets$20.1 $16.6 
Other assets40.8 32.0 
Total capitalized contract acquisition costs, net$60.9 $48.6 
The Company recognized $18.2 million, $16.3 million, and $14.6 million of amortization of capitalized contract acquisition costs for the years ended December 31, 2024, 2023, and 2022, respectively.